ecrin-mdr-crcClinical2016colorectal cancerColorectal CancerInterventionalhttps://newmdr.ecrin.org/Study/2638699Japan8ECRIN MDRCompletedfalseA phase II trial of lenvatinib in patients with metastatic colorectal cancer after standard chemotherapy (NCCH1503,Lemon trial)Interventions: 24mg of lenvatinib is orally taken once daily. Primary outcome(s): Disease control rate Study Design: Single arm Non-randomized2016-08-152638699JPRN-UMIN000023446